Chen et al., 2012
|
Male |
Not Specified |
Diabetic Brown Norway rats, Akita mice, Wild-type littermates (C57BL/6 mice), PPARα 2/2 mice |
Non- diabetic Brown Norway rats, Akita mice, Wild-type littermates (C57BL/6 mice), PPARα 2/2 mice |
FF- 0.25 or 0.15% admixture with rodent chow for 3 and 7 weeks |
Western blot analysis & Immunohistochemistry - Expression of inflammatory markers in retinal cells, Fluorescein retinal angiography- Retinal neovascularization, Endothelial cell scratch wound assay- Detection of REC tube formation, Transwell inserts cell migration assay- Migration of REC |
Therapeutic efficacy of Fenofibrate in diabetic retinopathy |
Holm et al., 2019
Holm LJ, Haupt-Jorgensen M, Giacobini JD, Hasselby JP, Bilgin M, Buschard K. Fenofibrate increases very-long-chain sphingol ipids and improves blood glucose homeostasis in NOD mice. Diabetologia. 2019;62(12):2262-72.
|
Female |
Three-week-old |
Female NOD mice |
Female NOD mice |
0.1% FF |
Immunofluorescence- Pancreatic cell nature; Lipid measurement |
Therapeutic efficacy of fenofibrate in pancreatic lipidome |
Pearsall et al., 2019
Pearsall EA, Cheng R, Matsuzaki S, Zhou K, Ding L, Ahn B, et al. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes. PLoS One. 2019;14(2):1-17.
|
Female Brown Norway rats; Male Sprague Dawley rats; Wild type mice, Pparα-/- mice |
Brown Norway and Sprague Dawley rats -10 weeks old; Wild type mice and PPARα -/- mice- 24 weeks old |
Diabetic Brown Norway and Sprague Dawley rats; Diabetic Wild type mice and PPARα -/- mice |
Non- diabetic Brown Norway and Sprague Dawley rats; Non-diabetic Wild type mice and PPARα -/- mice |
Brown Norway - 0.03% and 0.015% FF; Sprague Dawley - Feno-FA 10 mg/kg/day intraperitoneally for 1 week |
Optokinetic tracking- Visual acuity, Electroretinograms- Retinal function, DNA fragmentation ELISA- Retinal apoptosis, MTT assay- Retinal cell viability, NADH oxidation assay- Retinal mitochondrial function, Seahorse extracellular flux analysis- PPARα’s effect on retinal mitochondria, Fluorescent detection of intracellular ROS, Mass spectrometry- Retinal proteomic analysis |
Neuroprotective efficacy of fenofibrate in diabetic retinopathy |
Liu et al., 2018
|
Not Specified |
12 weeks |
C57BL/6J-Ins2Akita
|
Littermate mice |
0.1% FF for 4 weeks |
Immunohistochemistry- Retinal cell oxidation, Nuclear extraction kit- Retinal nuclear protein extraction, Fluorometric assay- Retinal oxidative stress detection, Retinal vascular leakage assay, Western blot analysis- Expression of retinal nuclear of β-catenin, Nox4, p-LRP6, Nox2, SOD1; RT-PCR- RNA extraction from ARPE-19 cells |
Therapeutic efficacy of fenofibrate in diabetic retinopathy |
Zhang et al., 2016
Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y, et al. Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin Sci. 2016;130(8):625-41.
|
Male C57BL/6J mice, Male FGF21-KO mice |
8-10 weeks |
Non- diabetic C57BL/6J mice with FF treatment; Diabetic C57BL/6J mice; Diabetic C57BL/6J mice with FF treatment |
Non- diabetic C57BL/6J mice; |
FF- 100 mg/kg of body weight every other day for 3 or 6 months |
Echocardiography- Cardiac Functioning; Histological staining (H & E; Sirius Red, Oil Red O)- Fibre disruption, collagen and lipid accumulation in myocardium; Western blot assay- Autophagic markers examination; RT-qPCR- Protein and mRNA expression of Sirt1; Plasma biochemical index assay- FGF21, Triacylglycerol and cholesterol level in plasma |
Therapeutic efficacy of fenofibrate in diabetic cardiomyopthy |
WT with FF treatment, Diabetic WT, Diabetic WT with FF treatment; FGF21-KO with FF treatment, Diabetic FGF21-KO; Diabetic FGF21-KO with FF treatment. |
WT mice; FGF21-KO mice |